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Hepatocellular carcinoma is a multifactorial disease which is associated with a background of many causal risk
factors. Diabetes mellitus however is one of the most common co-morbid illnesses found in hepatocellular carcinoma
patients that are significantly associated with worsening of hepatocellular carcinoma development, patient prognosis
and survival. Therefore, efforts have been focused on understanding the mechanisms underlying progression of
hepatocellular carcinoma onset and development especially in diabetic patients. To our knowledge, there are no
reports which address the impact of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) along with epigenetic
regulations associated with increased risk of hepatocellular carcinoma confounded by diabetes mellitus. Therefore,
this mini-review focuses on the possible intermediary mechanisms involved in worsening the onset and progression of
hepatocellular carcinoma development confounded by diabetes mellitus. The first approach is to look at the role of
inflammatory mediators (TNF-α and IL-6) in apoptosis and inflammation during hepatocarcinogenesis through
monitoring levels of apoptotic regulators, B-cell lymphoma 2 protein which is encoded by BCL2 gene and apoptosis
regulator BAX known as bcl-2-like protein 4 which is encoded by the BAX gene. The second approach is to focus on
the possible epigenomic reprogramming that drives hepatocellular transformation since epigenetic modification of
DNA is a key feature in the pathogenesis of hepatocarcinogenesis. Both approaches may suggest role of using Bcl2
and Bax as apoptotic and inflammatory markers for hepatocellular carcinoma detection as well as the importance
impact of DNA methylation, hypomethylation or histone modifications as attractive candidates for early-detection
biomarkers of hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is the fifth most common
malignancy in the world with high morbidity and mortality
but its pathogenesis remains unclear [1]. Because primary
liver cancer is a growing concern showing poor prognosis
due to its rapid infiltrating power and complicating liver
cirrhosis; more attention were given to address the causal
risk factors that could be preventable and/or treatable [2].* Correspondence: maisa.mahmoud@dasmaninstitute.org
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article, unless otherwise stated.Several risk factors have been identified that contrib-
ute to the international burden of HCC such as chronic
infection with hepatitis B virus (HBV) and hepatitis C
virus (HCV), alcoholic liver disease, non-alcoholic steato-
hepatitis (NASH), diabetes mellitus (DM), obesity, intake
of aflatoxins-contaminated food, tobacco smoking, ex-
cessive alcohol drinking and genetically inherited dis-
orders (hemochromatosis, α-1 anti-trypsin deficiency,
porphyrias); [3]. HCC is phenotypically and genetically
heterogeneous tumor, reflecting in part the heterogeneity
of etiologic factors involved in (i) the onset of HCC devel-
opment that is also influenced by age, gender and ethnic
differences, (ii) the complexity of hepatocyte functions
and epigenome leading to neoplastic transformation and
(iii) the late stage of HCC development [2].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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olism, it is not surprising that DM is an epiphenomenon
of many chronic liver diseases such as chronic hepatitis,
fatty liver, liver failure and cirrhosis [4]. DM is a metabolic
disorder characterized by hyperglycemia which may pre-
dispose the liver to relative insulin resistant due to inad-
equate secretion or receptor insensitivity to endogenous
insulin. DM is one of the leading causes of blindness and
the most common cause of end-stage renal disease and
cardiovascular complications in developed countries. In
recent years, DM has been associated with increase risk
for several malignancies including breast, colon, kidney,
liver, endometrium and pancreatic cancers [5]. In addition,
DM as part of the insulin resistance syndrome, has been
implicated as a risk factor for non-alcoholic fatty liver
disease (NAFLD), including its most severe form non-
alcoholic steatohepatitis (NASH); which has been identi-
fied as a cause of both cryptogenic cirrhosis and HCC.
DM has been reported to cause a 2.5-fold greater risk
of HCC, however this significant association was in-
dependent to hepatitis viral infections (HBV and/or
HCV) or alcohol consumption as examined from 10
previously reported studies; those reports account for ~
90% of HCC cases [1,6]. Many case reports and case re-
views of HCC in NASH have showed the association of
DM and obesity on the increased risk of HCC and
have implicated age and advanced fibrosis as signifi-
cant risks. Insulin resistance and the resulting inflamma-
tory cascade, which are associated with the development
of NASH appears to mediate hepatocarcinogenesis in
HCC [1].
The association between DM and HCC has been dem-
onstrated in both case–control and cohort studies, sug-
gesting that DM is independent risk factor for the
development of HCC. These several lines of evidence in-
cludes; (i) findings that insulin resistance and DM were
shown to increase the progression of liver diseases that
preceded the development of HCC [6,7]; (ii) findings
showing that 2.5 fold increase in the risk of HCC was
reported in patients with DM [8,9] attributed with
the prolonged DM disease duration [10-12]; (iii) find-
ings demonstrating the synergistic interaction between
DM and other HCC risk factors [11,13,14]; (iv) findings
showed significant association of DM for the recurrence
of HCC after treatment [15,16]; (v) findings suggesting
significant biological plausibility underlying the associ-
ation between DM and HCC [7,17].
Nevertheless, the exact pathophysiological mechanisms
of this significant association are still unclear. In this mini-
review, we aim to further analyze this relationship by
evaluating the role of possible intermediary mechanisms
that could be associated with the onset and progression of
HCC development in the presence of DM. We will mainly
focus on; (i) pro-inflammatory gene products (TNF-α andIL-6) and (ii) the epigenetic pathogenesis of DM on the
development of HCC.
Possible intermediary mechanisms involved in
worsening the onset and progression of
hepatocellular carcinoma confounded by diabetes
mellitus
TNF-α/ NF-kβ and IL-6/STAT-3 signaling pathways effect
on hepatocellular carcinoma development
Malignant transformation of hepatocytes may occur through
a pathway of increased liver cell turnover induced by
chronic liver injury and regeneration in the context of
inflammation, immune response and oxidative DNA
damage [18]. This is evidence to suggest that chronic in-
flammation in the individuals with diabetes mellitus type
2 (T2DM) may influence certain cancers via cytokines.
Cancerous and precancerous tissue show signs of inflam-
mation, which is caused by the infiltration of the immune
cells into the tissues. The presence of inflammatory cyto-
kines is important constituents of the local environment
of tumors in certain type of cancer including HCC. These
cytokines cause oncogenic changes that promote tumor
development by blocking apoptosis and increasing the
survival of malignant cells [19]. Although an elevation in
the circulating levels of tumor necrosis factor-alpha (TNF-
α), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12
(IL-12), interleukin-1-beta (IL-1β) and transforming growth
factor beta (TGF-β-1) has been observed in obese and dia-
betic individuals [20-24]; plasma levels of interleukin-10
(IL-10) were found elevated in obese individuals thus, de-
creased in diabetics [25].
Cytokines such as IL-1β, TNF-α, IL-8 and IL-6 have
been involved in chronic liver inflammation and patho-
genesis of various liver diseases; among which IL-6 and
TNF-α, are thought to be most important [26-28]. In
this regard, TNF-α and IL-6 were found to positively
correlated with the progression of HCC development in
humans [29-31].
IL-6 is a pleiotropic cytokine secreted by T cells, mac-
rophages, kupffer cells, and adipose tissue. Similarly,
TNF-α is secreted by several inflammatory cell types, in-
cluding monocyte/macrophages, neutrophils, T-cells,
kupffer cells and adipose tissue [26,32]. Increased circu-
lating levels of IL-6 and TNF-α have been found in
animal models and patients with liver disease including
HCC [33]. Moreover, studies have revealed that the
levels of TNF-α and IL-6 are significantly increased in
rats bearing hepatoma, which reflects an aggressive in-
flammatory response correlated with tumor induction [34].
In obesity and DM, tremendous amount of the tumor-
promoting cytokines IL-6 and TNF-α are produced, which
is thought to promote HCC development [35,31]. More-
over, DM-mediated inflammatory responses lead to
the production of cytokines, which act as growth and
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founding effects on the factors of inflammation, prolifera-
tion and anti-apoptosis in HCC, which explains why HCC
and DM co-occur twice as frequently as expected. Fur-
thermore, it has been reported that diabetic patients with
HCC are suffer more frequently with liver injury and
tumor growth as compared to non-diabetics [19].
IL-6 and TNF-α are involved in multiple signalling path-
ways, which ultimately lead to liver injury, inflammation
and HCC development (Figure 1). Chronic inflammation
in diabetic patients may promote carcinogenesis through
multifaceted processes such as activation of signal trans-
ducer and activator of transcription 3 (STAT-3) and nu-
clear factor kappa-light-chain-enhancer of activated B
cells (NF-kβ) transcription factors following the produc-
tion of tumor growth factors or induction of angiogenesis.
It is known that STAT-3, activated by IL-6 in hypatocytes,
promotes HCC cell growth in vitro and in vivo [36]. In
addition, activated IL-6/STAT-3 pathways have been ob-
served in liver cancer and are thought to be important fac-
tors in the initiation, development, and progression of
HCC [37,38]. Furthermore, blockade of STAT-3 may have
therapeutic potential in preventing and treating liver can-
cer [39]. Since serum concentrations of IL-6 are elevated
in diabetic patients, it is reasonable to surmise that IL-6-Figure 1 Oncogenic impact of IL-6/STAT-3 and TNF-α/NF-kβ signaling
induced type-2 diabetes, produces IL-6 and TNF-α by accessory cells, adipo
activate the downstream signaling molecules STAT-3 and NF-kβ in residual liv
pathways are likely to be involved in critical processes such as anti-apoptosis, pactivated STAT-3 signaling pathway plays play a role in
HCC development in DM. The oncogenic role of constitu-
tively activated STAT-3 is driven through the up-regulation
of cell survival proteins (Bcl-xL, BCL-2) and cell cycle regu-
lators (c-Myc, cyclin D) [38,40-42]. The second main
HCC oncogenic pathway is TNF-α-mediated activation of
NF-kβ, which is a key regulator of inflammation that pro-
vides a mechanistic link between inflammation and apop-
tosis during carcinogenesis [43]. Constitutively increased
NF-kβ activation has been observed in tumor tissues [44];
however, IKK-α, a critical kinase for NF-kβ activation, is
necessary to produce malignant properties in liver cancer
[45]. NF-kβ activation not only protects tumor cells
against cell death but also provides essential growth fac-
tors to non-parenchymal cells of the liver, such as Kupffer
cells [46,47]. TNF-α-mediated NF-kβ activation has both
positive and negative impact on our immune system
[48,49]. An imbalance in TNF-α mediated NF-kβ could
lead to several types of inflammatory disorders. In DM,
a balance shift towards a prolonged activation of IKK-α/
NF-kβ, and simultaneous blockade of apoptosis, is essen-
tial for the inhibition of tumor growth. TNF-α induced ac-
tivation of mitogen-activated protein kinases (MAPKs) are
also significant factors for tumour growth. TNF-α levels
were shown to be higher in obese and diabetic individualspathways on the development and progression of HCC. Obesity
se tissue and Kupffer cells. These inflammatory markers (IL-6 and TNF-α)
er cells, respectively. This activation of NF-kβ and STAT-3 signaling








Hepatocyte Proliferave & 
Oncogenic Transformaon
Hepatocellular Carcinoma
Figure 2 Overview of the possible intermediary mechanisms
associated with onset and progression of hepatocellular
carcinoma confounded by diabetes mellitus; (i) possible effects
of IL-6 and TNF-α as apoptotic and inflammatory markers for
the development of HCC and (ii) role of epigenomic reprogramming
that drives hepatocellular transformation.
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[27,32,50]. In addition, increased STAT-3 and NF-kβ were
shown to be correlated with impaired insulin sensitivity
and more advanced development of T2DM. Furthermore,
systemic abnormalities in the activation of STAT-3 and
NF-kβ in subjects with DM provide clinically important
milieu for increased risk of severe HCC development
[51,52]. Since the presence of TNF-α and IL-6 is consid-
ered to be a possible risk factor for the development of
HCC in diabetic individuals, DM is thought to be a major
risk factor for the development of aggressive HCC. In con-
clusion, these studies suggest that the presence of liver in-
flammation in the context of DM, leads to the exposure of
hepatocytes to increased levels of IL-6 and TNF-α, which
promote the activation of JAK/STAT-3 and IKKα/NF-kβ
signaling pathways, followed by lack of apoptosis, and
consequently uncontrolled proliferation of hepatocytes;
this results in initiation and promotion of HCC develop-
ment [53].
Epigenomic reprogramming that drives hepatocellular
transformation
Multifactorial diseases such as DM and HCC are far more
complex compared to single gene disorders; whereby mul-
tiple genes in addition to non-genetic components dictate
the pathogenic manifestations of the disease. Further
sophistication layer is added onto these disorders from
modifications on the genetic material in cells and tissues.
These are referred to as “epigenetics factors”. Epigenetic
(meaning “above” genetics) inheritance is essential for the
development of critical cellular processes such as gene
transcription, differentiation and protection against viral
genomes. Aberrant epigenetic states may predispose to
genetic changes or vice versa [54-56]. Therefore, epigen-
etic and genetic mechanisms may work together to silence
key cellular genes and destabilize the genome, leading to
oncogenic transformation and observed complexity and
heterogeneity in human cancers. The main epigenetic
modifications that can alter gene expression and tissue-
specific cellular changes [57] are DNA methylations, his-
tone modifications, and non-coding RNAs (micro and
long non-coding RNAs); that together impact on tran-
scriptional regulation of wide range of genes [58,59]. Thus,
unregulated epigenetic events play key role in pathogenic
mechanisms affecting the expression of many genes in-
cluding tumor-suppressor genes and cancer-associated
genes as has been observed in broad human cancers [60].
Moreover, a number of studies suggested that a frequent
loss of heterozygosity (LOH) in chromosome 8p in HCC
cases which leads to inactivation of the Deleted in Liver
Cancer 1 gene (DLC-1) may play a pivotal role in HCC
development [61]. Thus, in the late stage of HCC de-
velopment; somatic mutations in several tumor suppres-
sor genes (such as TP53, p16 and RB); oncogenes (such asc-MYC and β-catenin) and other cancer-associated genes
including E-cadherin and cyclin D1 have also been ob-
served. However, the significance and sequence of these
genetic events remain to be established [61,62].
Recent data suggest that the epigenetic pattern is age-
dependent influencing key mitochondrial respiratory chain
genes [63,64]. An example is the complex 4 COX7A1 pro-
tein (which is a target of age-related DNA methylation) as
evidenced from its expression reduction in muscle tissue
from diabetic patients [64,65]. In young and elderly twin
studies; COX7A1 gene promoter methylation was shown
to be increased in skeletal muscles of elderly compared
with young twins, and that was reciprocal to expression
pattern of COX7A1 gene. The transcript level of COX7A1
gene in skeletal muscle was associated with increased
in vivo glucose uptake [64]. Polymorphism can also lead to
generation of DNA methylation sites (CpG dinucleotides).
In addition, putative transcription factor binding site in
the NDUFB6 promoter are associated with increased
DNA methylation, decreased gene expression, and de-
creased in vivo metabolism with increasing age [66].
The impact of aging on T2DM is also evident from data
on the hepatic function of glucokinase enzyme glucose
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patients’ liver [67]. Further evidence for epigenetic role
was demonstrated in a recent study in which significant
differential DNA methylation profiling was indicated
when comparing pancreatic islets from type 2 diabetics
with non-diabetic controls; where 276 CpG loci associated
with 254 genes were uncovered. These methylation signa-
tures were absent in peripheral blood cells of diabetic
individuals, and couldn’t be experimentally induced in
non-diabetic islets by exposure to high glucose, suggesting
tissue-specific methylation patterns [68]. There is also the
potential role for epigenetic control microRNAs (miRNAs)
on chromatin-modifying enzymes leading to effects in
gene expression. Histone modifications and changes in
chromatin structure can affect transcription and expres-
sion of miRNAs [69]; which are associated with the
regulation of pathogenic pathways critical in insulin
secretion, cholesterol synthesis and fat metabolism [70-72].
Increased telomeric activity and hTERT expression in
HCC cases were also reported. In one study on 106 hep-
atic tissues with and without HCC; hTERT expression has
correlated inversely with DNA methylation levels in nor-
mal tissues compared to tumor tissues in a mechanism
thought to be regulated by DNA methylation and histone
H3-K9 modifications [73].
Furthermore, genome-wide oncogenes promoter de-
methylation was detected during HCC progression [74].
This demethylation was accompanied by selective regional
hypermethylation in the CpG islands leading to silencing
of antitumor genes like tumor suppressor genes, prolifera-
tion inhibitor genes, in addition to apoptotic and DNA
repair genes [75,76]. A proposed mechanism for HCC
is suggested to occur via activating inflammatory re-
sponse components’ (NF-κB and JAK/STAT) to induce
epigenetic changes resulting in switching on the long-
term oncogenic memory system in hepatocytes [77]. The
epigenetic switch in turn would contribute to a chronic
inflammatory response during the course of altered gene
expression concordant with a positive feedback loop to
aggravate a chronic state of inflammation. These un-
controlled epigenetic-driven transcriptional alterations ul-
timately promote hepatocytes proliferative and oncogenic
transformations.
Conclusions
In this mini-review, we summarized the intermediary
mechanisms conveying the association between DM and
HCC development. Whereby, in the first section, we
highlighted that DM can work as a promoter for HCC
development since number of evidence lines showed
that it may worsen the HCC progression as evident by
co-existence of pro-inflammatory gene products (TNF-α
and IL-6) during hepatocarcinogenesis. These inflamma-
tory markers play a role in monitoring levels of apoptoticregulators (Bcl2 and Bax), suggesting their importance as
apoptotic and inflammatory markers for HCC. The sec-
ond section, we have focused on the possible effects of
epigenetic mechanisms of HCC upon co-existence of DM.
Number of studies showed that DNA methylation, histone
modifications, and RNA interference, may lead to acti-
vation of pro-inflammatory signaling (NF-κB and JAK/
STAT) and deregulation of metabolic pathways. The
crosstalk of chromatin-modifying enzymes, microRNAs,
signaling pathways and the downstream transcription fac-
tors may result in epigenomic reprogramming that drives
hepatocellular transformation. Many of the epigenetic
events and methylated genes described previously in other
studies have been detected in premalignant tissues and
in the serum of patients prior to or concurrent with
the diagnosis of cancer. For this reason, DNA methyla-
tion, hypomethylation or histone modifications are attract-
ive candidates for early-detection biomarkers (Figure 2).
Future trends
Inflammatory markers (TNF-α and IL-6) can be sug-
gested to be used as diagnostic tools for HCC along with
alpha-fetoprotein (AFP) that may help to monitor the se-
verity of hepatocellular damage and hepatic function in
diabetic patients. These markers can also help to follow-
up patients diagnosed with HCC prognostically. On the
other hand, epigenetic alterations could be used as bio-
markers of early-detection for HCC which may help in
prognosticate diabetic patient outcomes or even as novel
therapeutic compounds. However, large-scale prospective
data is warranted before this approach can be translated
into personalized medicine.
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